Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.31 |
| ▸ | IDH2 | P48735 | 2/20 | 0.31 |
| ▸ | FOS | P01100 | 2/20 | 0.31 |
| ▸ | JUN | P05412 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.31 |
| ▸ | RELA | Q04206 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248176 | 0.76 | JUN (0.35) | TRPV3PDE4BFOSJUNNFKB1 | |
| SCHEMBL31416631 | 0.76 | HEXA (0.36) | FOSJUNNFKB1NFKB2RELA | |
| SCHEMBL31416682 | 0.76 | JUN (0.32) | TRPV3FOSJUNNFKB1NFKB2 | |
| SCHEMBL24850642 | 0.76 | PDE4B (0.34) | TRPV3PDE4BIDH1IDH2FOS | |
| SCHEMBL14504516 | 0.76 | PDE4B (0.34) | TRPV3PDE4BIDH1IDH2 | |
| SCHEMBL19301738 | 0.72 | DHFR (0.36) | — | |
| SCHEMBL22868494 | 0.71 | CYP3A4 (0.34) | TRPV3PDE4BIDH1 | |
| SCHEMBL25165378 | 0.71 | PDE4B (0.39) | PDE4BIDH1IDH2 | |
| Formamide SCHEMBL28472309 | 0.71 | TKT (0.34) | PDE4BFOSJUNNFKB1NFKB2 | |
| SCHEMBL14809757 | 0.71 | GABRP (0.45) | PDE4BFOSJUNNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | TRPV3 2536/4885PDE4B 70/4885IDH1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.